ReviewJournal of translational autoimmunity2026
Targeting the NLRP3 inflammasome in immune cells: A new frontier in autoimmune disease research.
Review in Journal of translational autoimmunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aberrant immune cell activation contributes to autoimmune onset and progression, where emerging evidence demonstrates a critical role for NLRP3 inflammasome activation in this context. NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) is a well-known innate pattern recognition receptor (PRR) that is also expressed in adaptive immune cells. Two steps are required for full inflammasome activation: priming and activation. Following NLRP3 activation, caspase-1 cleaves pro-IL-1β and pro-IL-18, leading to their secretion, creating a pro-inflammatory milieu that can enhance the onset and progression of autoimmune diseases. Moreover, NLRP3 activation drives immune cells toward an inflammatory phenotype. Discovering the precise role of the NLRP3 inflammasome in immune cells opens a new avenue for treating autoimmune diseases. This review highlights the function of the NLRP3 inflammasome in innate and adaptive immune cells in the context of autoimmune disorders and discusses therapeutic targeting strategies, emphasizing areas for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.